Bristol Myers Squibb (NYSE:BMY - Get Free Report)'s stock had its "hold (c-)" rating restated by analysts at Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.
Several other research firms have also issued reports on BMY. Citigroup reiterated a "neutral" rating on shares of Bristol Myers Squibb in a report on Monday. Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective on the stock. in a research note on Tuesday, August 5th. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Dbs Bank upgraded Bristol Myers Squibb to a "moderate buy" rating in a research note on Thursday, October 2nd. Finally, Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $57.14.
View Our Latest Analysis on BMY
Bristol Myers Squibb Trading Down 0.1%
NYSE:BMY traded down $0.03 on Tuesday, reaching $43.51. The company's stock had a trading volume of 6,272,938 shares, compared to its average volume of 13,528,041. Bristol Myers Squibb has a 1-year low of $42.96 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The firm has a market cap of $88.56 billion, a PE ratio of 17.54, a PEG ratio of 2.26 and a beta of 0.33. The business's 50-day moving average price is $46.22 and its two-hundred day moving average price is $47.84.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company's revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities research analysts anticipate that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.
Insider Buying and Selling at Bristol Myers Squibb
In related news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.07% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. OFI Invest Asset Management raised its position in Bristol Myers Squibb by 67.4% during the 3rd quarter. OFI Invest Asset Management now owns 2,828 shares of the biopharmaceutical company's stock worth $128,000 after purchasing an additional 1,139 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Bristol Myers Squibb by 14.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 639,973 shares of the biopharmaceutical company's stock worth $28,863,000 after acquiring an additional 83,214 shares in the last quarter. Kentucky Trust Co raised its position in shares of Bristol Myers Squibb by 12.9% in the 3rd quarter. Kentucky Trust Co now owns 8,475 shares of the biopharmaceutical company's stock worth $382,000 after acquiring an additional 970 shares in the last quarter. Cohen Investment Advisors LLC raised its position in shares of Bristol Myers Squibb by 14.2% in the 3rd quarter. Cohen Investment Advisors LLC now owns 9,469 shares of the biopharmaceutical company's stock worth $427,000 after acquiring an additional 1,180 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC grew its stake in shares of Bristol Myers Squibb by 2.9% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 10,497 shares of the biopharmaceutical company's stock valued at $473,000 after buying an additional 291 shares during the period. 76.41% of the stock is owned by institutional investors.
Bristol Myers Squibb Company Profile
(
Get Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.